

PATENT OWNER  
EXHIBIT 2027



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/315,445	12/10/2002	Tony Marcel	239682US0 CONT	4601
22850	7590	05/26/2010	EXAMINER	
OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, L.L.P. 1940 DUKE STREET ALEXANDRIA, VA 22314			BUNNER, BRIDGET E	
			ART UNIT	PAPER NUMBER
			1647	
			NOTIFICATION DATE	DELIVERY MODE
			05/26/2010	ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com  
oblonpat@oblon.com  
jgardner@oblon.com

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE BOARD OF PATENT APPEALS  
AND INTERFERENCES

---

*Ex parte* TONY MARCEL,  
FRANCOIS ROUGEON, and CATHERINE ROUGEOT

---

Appeal 2009-010632<sup>1</sup>  
Application 10/315,445  
Technology Center 1600

---

Decided:<sup>2</sup> May 24, 2010

---

Before LORA M. GREEN, FRANCISCO C. PRATS, and  
JEFFREY N. FREDMAN, *Administrative Patent Judges*.

PRATS, *Administrative Patent Judge*.

DECISION ON APPEAL

This appeal under 35 U.S.C. § 134 involves claims to peptide-containing pharmaceutical compositions. The Examiner rejected the claims for lack of enablement and lack of written description.

---

<sup>1</sup> Institute Pasteur is the real party in interest (App. Br. 1).

<sup>2</sup> Oral argument was presented in this case on May 13, 2010.

We have jurisdiction under 35 U.S.C. § 6(b). We reverse.

STATEMENT OF THE CASE

Claims 45-55 are pending (App. Br. 1). Claims 52-55 have been withdrawn from consideration by the Examiner (*id.*). Claims 45-51 stand rejected and are on appeal (*id.*).

Claim 45, the sole independent claim on appeal, reads as follows:

45. A composition, comprising:

a peptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and

a pharmaceutical agent capable of treating impaired sexual behavior in a mammal having impaired sexual behavior,

wherein the amount of the pharmaceutical agent in the composition alone is not sufficient to treat impaired sexual behavior in a mammal having impaired sexual behavior and wherein the amount of the peptide and the pharmaceutical agent together is sufficient to treat impaired sexual behavior in a mammal having impaired sexual behavior.

The Examiner cites the following documents as evidence of unpatentability:

Vishnu M. Dhople and Ramakrishnan Nagaraj, *Conformation and activity of  $\delta$ -Lysin and its analogs*, 26 PEPTIDES 217-225 (2005).

Thomas Frei et al., *Different Extracellular Domains of the Neural Cell Adhesion Molecule (N-CAM) Are Involved in Different Functions*, 118 J. CELL BIOL. 177-194 (1992).

GOODMAN AND GILMAN'S, THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 8<sup>th</sup> ed., pages 33-48 (1993).

Johanne Louise Neiiendam et al., *An NCAM-derived FGF-receptor agonist, the FGL-peptide, induces neurite outgrowth and neuronal survival in primary rat neurons*, 91 J. NEUROCHEM. 920-935 (2004).

The following rejections are before us for review:

(1) Claims 45-51, rejected under 35 U.S.C. § 112, first paragraph, as lacking enablement for the full scope of the claimed subject matter (Ans. 3-8); and

(2) Claims 45-51, rejected under 35 U.S.C. § 112, first paragraph, as lacking written description (*id.* at 8-10).

During prosecution, the Examiner made a species election requirement between the sequences recited in claim 45, and in response to Appellants' election, examination of the claims was limited to SEQ ID NO: 2 (*see* Final Rejection 3 (entered January 24, 2008)).

We limit our consideration of the merits of the appealed rejections to the elected species. *See Ex parte Ohsaka*, 2 USPQ2d 1460, 1461 (BPAI 1987).

## ENABLEMENT

### ISSUE

The Examiner concedes that the Specification enables (a) a composition “comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 2,” and (b) a composition comprising a peptide “consisting of the amino acid sequence of SEQ ID NO: 2 in an amount sufficient to increase the number and duration of sexually-related behaviors in male rats (increased non-sexual contact, increased latency of the first mount; increased number of ejaculations per sexual episode, and increased number of mounts with intromissions)” (Ans. 3-4).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.